Liv.52 in alcoholic liver disease: A prospective, controlled trial

H. A. De Silva*, P. A.M. Saparamadu, M. I. Thabrew, A. Pathmeswaran, M. M.D. Fonseka, H. J. De Silva

*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلةArticleمراجعة النظراء

37 اقتباسات (Scopus)


Liv.52, a hepatoprotective agent of herbal origin, is used empirically for the treatment of alcoholic liver disease in Sri Lanka. We conducted a controlled trial to assess the efficacy of Liv.52 in patients with alcoholic liver disease. Patients with evidence of alcoholic liver disease attending outpatient clinics were included in a prospective, double blind, randomized, placebo controlled trial. During the trial period, 80 patients who fulfilled inclusion criteria were randomly assigned Liv.52 (cases; n=40) or placebo (controls) the recommended dose of three capsules twice daily for 6 months. All patients underwent clinical examination (for which a clinical score was computed), and laboratory investigations for routine blood chemistry and liver function before commencement of therapy (baseline). Thereafter, clinical assessments were done monthly for 6 months, while laboratory investigations were done after 1 and 6 months of therapy. There was no significant difference in the age composition, alcohol intake and baseline liver function between the two groups. The two-sample t-test was used to analyze data obtained after 1 and 6 months of therapy against baseline values. There was no significant difference in clinical outcome and liver chemistry between the two groups at any time point. There were no reports of adverse effects attributable to the drug. Our results suggest that Liv.52 may not be useful in the management of patients with alcohol induced liver disease.

اللغة الأصليةEnglish
الصفحات (من إلى)47-50
عدد الصفحات4
دوريةJournal of Ethnopharmacology
مستوى الصوت84
رقم الإصدار1
المعرِّفات الرقمية للأشياء
حالة النشرPublished - يناير 1 2003
منشور خارجيًانعم

ASJC Scopus subject areas

  • ???subjectarea.asjc.3000.3004???
  • ???subjectarea.asjc.3000.3002???


أدرس بدقة موضوعات البحث “Liv.52 in alcoholic liver disease: A prospective, controlled trial'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا